View Clinical Trial (Medical Research Study)

Beef in an Optimal Lean Diet (BOLD) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors: Effects on Metabolic Syndrome - NCT00937638-16802(Clinical Trial 301491)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  University Park
State:  
PA
Zip Code: 16802
Conditions: Metabolic Syndrome - Cardiovascular Disease
Purpose: The proposed research will provide important information about the role of 2 intervention diets that provide different amounts of lean beef and meet current nutrient recommendations for the treatment of Metabolic Syndrome (MetSyn), a chronic disease that is still increasing in prevalence at alarming rates. The experimental and diet designs will enable us to evaluate lifestyle interventions for MetSyn for persons who maintain weight, lose weight and maintain their weight loss, as is currently recommended in clinical practice. Importantly, the investigators will compare a diet high in lean beef (5 oz/day) which is compositionally similar (i.e., energy and nutrients) to the modified-DASH diet, a low beef diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors, including MetSyn. In addition, the investigators also will evaluate a moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet, on CVD risk factors in persons with MetSyn. Hypotheses: 1. Healthful isocaloric diets that include lean beef as the primary source of protein (BOLD diet) with average (18%; BOLD) or moderate-high (28%; BOLD+) total protein intake will show similar or greater reductions in CVD risk, respectively when compared to a modified-DASH diet. 2. A healthful weight-loss diet, including lean beef as the primary source of protein in a high-moderate protein diet (BOLD+ diet), plus regular exercise (BOLD+ + ex) will reduce body weight equal to that of a BOLD + ex and DASH + ex intervention, but may improve CV risk factors (such as BP and TG), and therefore reduce the prevalence of MetSyn more than a BOLD + ex and DASH + ex intervention. 3. The BOLD diet will be more effective than the modified-DASH diet, and the BOLD+ diet more effective than the BOLD diet in maintaining the CVD benefits attained during phases 1 and 2. Dietary adherence will be better on the BOLD and BOLD + diets compared with the modified DASH diet.
Study summary:
Criteria: Inclusion Criteria: - (BMI 27-42 kg/m2) - Three or more of the following risk factors (defined as having MetSyn): - abdominal obesity [waist circumference > 102 cm (40 inches) in men and > 88 cm (35 inches) in women], - elevated blood glucose [> 100mg/dl (5.6 mmol/L)] - elevated TG [150 mg/dl (1.7 mmol/L)] - low HDL-C [<40 mg/dl (1.03 mmol/L) in men and > 50 mg/dL (1.29 mmol/l) in women] - hypertension (SBP > 130 mmHg or DBP > 85 mmHg)* Exclusion Criteria: - A history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on medication) - Lactation, pregnancy, or desire to become pregnant during the study - Intake of putative cholesterol-lowering supplements (psyllium, fish oil capsules, soy lecithin, niacin, fiber, flax, and phytoestrogens, stanol/sterol supplemented foods) - High alcohol consumption (≥ 14 drinks/week) - Participation in regular physical activity (> 1 formal session/week) - Lipid, BP or glucose lowering medication
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: July 21, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.